• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 40-17F2 filed by Daxor Corporation

    6/13/25 6:22:14 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care
    Get the next $DXR alert in real time by email
    40-17F2 1 form40-17f2.htm 40-17F2

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM N-17f-2

     

    Certificate of Accounting of Securities and Similar

    Investments in the Custody of

    Management Investment Companies

     

    Pursuant to Rule 17f-2 [17 CFR 270.17f-2]

     

    1. Investment Company Act File Number: 811-22684   Date examination completed:
         
        December 31, 2024
    2. State identification Number:
        AL   AK   AZ   AR   CA   CO
        CT   DE   DC   FL   GA   HI
        ID   IL   IN   IA   KS   KY
        LA   ME   MD   MA   MI   MN
        MS   MO   MT   NE   NV   NH
        NJ   NM   NY X   NC   ND   OH
        OK   OR   PA   RI   SC   SD
        TN   TX   UT   VT   VA   WA
        WV   WI   WY   PUERTO RICO        
       

    Other

    (specify):

                       
    3. Exact name of investment company as specified in registration statement:
     
    Daxor Corporation
     
    4. Address of principal executive office (number, street, city, state, zip code):
     

    109 Meco Lane, Oak Ridge, TN 37830

     

     

     

     

     

     

     

     

    Management Statement Regarding Compliance with

    Certain Provisions of the Investment Company Act of 1940

     

    March 3, 2025

     

    We, as members of management of Daxor Corporation, (the “Company”) are responsible for complying with the requirements of subsections (b) and (c) of Rule 17f-2, “Custody of Investments by Registered Management Investment Companies,” of the Investment Company Act of 1940. We are also responsible for establishing and maintaining effective internal controls over compliance with those requirements. We have performed an evaluation of the Company’s compliance with the requirements of subsections (b) and (c) of Rule 17f-2 as of December 31, 2024, and for the period from September 30, 2024 through December 31, 2024.

     

    Based on this evaluation, we assert that the Company was in compliance with the requirements of subsections (b) and (c) of Rule 17f-2 of the Investment Company Act of 1940 as of December 31, 2024, and for the period from September 30, 2024 through December 31, 2024, with respect to securities reflected in the investment accounts of the Company.

     

    Daxor Corporation

     

    /s/ Michael Feldschuh  
    Michael Feldschuh  
    President and Chief Executive Officer  
       
    /s/ Robert J. Michel  
    Robert J. Michel  
    Chief Financial Officer  
    Chief Compliance Officer  

     

     

     

     

    Independent Public Accountant’s Report

     

    To the Board of Directors and Shareholders of Daxor Corporation,

     

    We have examined management of Daxor Corporation (the “Company”) assertion, included in the accompanying Management Statement Regarding Compliance with Certain Provisions of the Investment Company Act of 1940, that the Company complied with the requirements of subsections (b) and (c) of Rule 17f-2, under the Investment Company Act of 1940 (the “Act’’) (the “specified requirements”) as of December 31, 2024. Daxor Corporation’s management is responsible for its assertion. Our responsibility is to express an opinion on management’s assertion about the Company’s compliance with the specified requirements based on our examination.

     

    Our examination was conducted in accordance with attestation standards established by the AICPA. Those standards require that we plan and perform the examination to obtain reasonable assurance about whether management’s assertion about compliance with the specified requirements is fairly stated, in all material respects. An examination involves performing procedures to obtain evidence about whether management’s assertion is fairly stated in all material respects. The nature, timing, and extent of the procedures selected depend on our judgement, including an assessment of the risks of material misstatement of management’s assertion, whether due to fraud or error. We believe that the evidence we obtained is sufficient and appropriate to provide a reasonable basis for our opinion.

     

    We are required to be independent and to meet our other ethical responsibilities in accordance with relevant ethical requirements relating to the engagement.

     

    Included among our procedures were the following tests performed as of December 31, 2024, and with respect to the agreement of security purchases and sales, for the period from September 30, 2024 (the date of the last examination), through December 31, 2024:

     

    ●Confirmation of all securities held by custodians in book entry form including UBS Financial Services Inc. and Continental Stock Transfer & Trust
       
    ●Reconciliation of all such securities to the books and records of the Company and the custodians
       
    ●Agreement of all security purchases and all security sales or maturities since the last report from the books and records of the Company to custodian confirmations

     

    Our examination does not provide a legal determination on the Company’s compliance with the specified requirements.

     

    In our opinion, management’s assertion that Daxor Corporation complied with the requirements of subsections (b) and (c) of Rule 17f-2 of the Investment Company Act of 1940 as of December 31, 2024, with respect to securities reflected in the investment account of the Company is fairly stated, in all material respects.

     

    This report is intended solely for the information and use of management and the Board of Directors of Daxor Corporation and the Securities and Exchange Commission and is not intended to be, and should not be, used by anyone other than the specified parties.

     

    /s/ Bush & Associates CPA LLC

     

    We have served as the Company’s auditor since 2024.

     

    Henderson, Nevada

    March 3, 2025

    PCAOB ID Number 6797

     

     

     

    Get the next $DXR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Michel Robert J bought 3,000 units of Daxor Common Stock, increasing direct ownership by 18% to 20,050 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    12/11/25 3:46:46 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Scientific Officer Feldschuh Jonathan Adam bought 18,000 units of Daxor Common Stock, increasing direct ownership by 50% to 53,908 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    12/11/25 3:41:44 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Jefferies John bought 2,344 units of Daxor Common Stock, increasing direct ownership by 15% to 17,616 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    11/14/25 5:22:37 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    SEC Filings

    View All

    SEC Form 40-8F-2 filed by Daxor Corporation

    40-8F-2 - DAXOR CORP (0000027367) (Filer)

    2/9/26 4:01:57 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - DAXOR CORP (0000027367) (Filer)

    1/26/26 4:58:54 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    SEC Form 424B4 filed by Daxor Corporation

    424B4 - DAXOR CORP (0000027367) (Filer)

    1/23/26 9:24:06 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital initiated coverage on Daxor with a new price target

    Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00

    3/25/21 12:00:28 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Michel Robert J bought 3,000 units of Daxor Common Stock, increasing direct ownership by 18% to 20,050 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    12/11/25 3:46:46 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Scientific Officer Feldschuh Jonathan Adam bought 18,000 units of Daxor Common Stock, increasing direct ownership by 50% to 53,908 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    12/11/25 3:41:44 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Jefferies John bought 2,344 units of Daxor Common Stock, increasing direct ownership by 15% to 17,616 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    11/14/25 5:22:37 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business

    Oak Ridge, TN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 (the Investment Company Act) to the Securities Exchange Act of 1934 (the "Exchange Act"), subject to its completion of required regulatory filings and approvals. This transition reflects the sustained rapid scaling and strategic maturation of the Company's core diagnostic technology operating business. The Company's principal focus remains the development and commercialization of its market-leading Blood Volume Analysis (BVA) t

    2/10/26 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation Announces $9 Million Registered Direct Offering

    OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) ("Daxor" or the "Company") announced today that it has entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock (the "Shares") at a purchase price per Share of $11.75. The offering is expected to close on or about January 26, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering to the Company are expected to be approximately $9 million, before deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds fr

    1/23/26 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer

    Continued Integration of ezBVA Lab Service and On-Site Analyzer Deployment Signals Accelerating Market Traction Oak Ridge, TN, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces the expansion of its Blood Volume Analysis (BVA) platform into three new, prestigious facilities. This milestone demonstrates the accelerating market adoption of BVA's pivotal role in precision fluid management, leading to improved patient outcomes and reduced healthcare costs. This growth is propelled by Daxor's dual-solution strategy: the initial onboarding of our new on-site BVA analyzer at select locations and CLIA-certified ez

    11/25/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Leadership Updates

    Live Leadership Updates

    View All

    Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer

    Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer. As part of his new responsibilities, Dr. Jefferies will leverage his extensive expertise to advise Daxor on strategic clinical and medical affairs matters and to facilitate the collaboration between the Company and healthcare professionals. He will be a key advisor, offering insights to inform corporate development strategies and advance the organization's growth objectives. Michael Fe

    6/5/24 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation Appoints Linda Cooper, Vice President Project Management

    Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. "Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda's proven track record makes her an excellent addition to the Daxor team to lead our development projects including our next generation systems, as well as overseeing our operations at our Oak Ridge facility," said Michael Feldschuh, CEO and President of Daxor Corporation. Before joining Daxor, Linda has held several senior leadersh

    2/17/23 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Financials

    Live finance-specific insights

    View All

    Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

    Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, "Patience, persistence and perspiration make an unbeatable combination for success." – Napoleon Hill. This timeless wisdom resonates deeply with the journey we've undertaken at Daxor Corporation, and it perfectly encapsulates the spirit behind our latest achievements. We are thrilled to share that this persistence has culminated in a truly transformative moment for our company, marking an important

    9/2/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

    Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023. The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. D

    3/4/25 4:55:00 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

    Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. After Management's presentation, there will be an opportunity for Q&A. Investors are encouraged to submit questions in advance via email to: [email protected]. To participate, register HERE. A webcast replay of the call will be available on the Company's website at Daxor.com. About Daxor Corporation Daxor Corporatio

    3/4/25 3:53:00 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care